Breast cancer symposium: From San Antonio to Saint Gallen;De San Antonio à Saint-Gallen: Réflexions de Saint-Paul-de-Vence ou comment ne plus savoir à quel sein se vouer...

Bulletin du Cancer

Volumn 90, Issue 3, 2003, Pages 278-283

  Gligorov, Joseph ^a   Beuzeboc, Philippe ^b  

^a HÔPITAL TENON   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; GOSERELIN; LETROZOLE; METHOTREXATE; PLACEBO; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; FRANCE; HUMANS; NEOADJUVANT THERAPY; TEXAS;

EID: 0037882248     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002 ; 20 : 3576-7.
2. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer : nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst 2001 ; 30 : 96-102.
3. National Institutes of Health Consensus Development Conference statement : adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001 ; 30 : 5-15.
4. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights : international consensus panel on the treatment of primary breast cancer. 7th International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001 ; 19 : 3817-27.
5. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000 ; 342 : 525-33.
6. Cardoso F, Di Leo A, Piccart MJ. Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. Cancer Treat Rev 2002 ; 28 : 275-90.
7. Pandis N, Teixeira MR, Adeyinka A, et al. Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes Cancer 1998 ; 22 : 122-9
8. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001 ; 345 : 833-5.
9. Pager S. The distribution of secondary growths in cancer of the breast. Lancet 1889 ; 1 : 571-3.
10. Tamoxifen for early breast cancer : an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 1998 ; 351 : 1451-67.
11. Anastrozole alone or in combination with tamoxifen versus ramoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer : first results of the ATAC randomised trial. Lancet 2002 ; 359 : 2131-9.
12. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998 ; 339 : 357-63.
13. Andersen J, Poulsen HS. Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases : an immunohistochemical study in human breast cancer. Acta Oncol 1988 ; 27 : 761-5.
14. Brankovic-Magic MV, Nikolic-Vukosavljevic DB, et al. Variations in the content of steroid receptors in breast cancer : comparison between primary tumors and metastatic lesions. Acta Ontol 1992 ; 31: 629-33.
15. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001 ; 93 : 1141-6.
16. Cardoso F, Di Leo A, Latsimont D, et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001 ; 12 : 615-20.
17. Harbeck N, Kates RE, Look M, Klinj JGM, Schmitt M, Foenkens JA. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-I. Breast Cancer Research and Treatment 2002 ; 76, (Abstr 7).
18. Harbeck N, Kates RE, Look M, Meijer-van Gelder ME, Klinj JGM, Ktüger A, et al Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and Plasminogen Activator Inhibitor type I (n = 3424). Cancer Res 2002 ; 62 : 4617-22.
19. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002 ; 20 : 1000-7.
20. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002 ; 347 : 1566-75.
21. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009.
22. Castiglione-Gettsh MM. Chemoedocrine therapy for node-negative breast cancer : International Breast Cancer Study Group (IBCSG) trials VIII and IX. Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 11.
23. Fisher B, Jeong JH, Bryant J, Mamounas EP, Dignam JJ, Wolmark N. Findings from decades of National Surgical Adjuvant Breast and Bowel Project clinical trials involving breast cancer patients with negative axillary nodes. Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 16.
24. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer : The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002 ; 20 : 4628-35.
25. Jakesz R, Hausmaninger H, Kubisra E, Gnant M, Menzel C, Bauernhofer T, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamde, methotrexate, and fluorouracil : evidence for the superiority of treatment with endocrine blockade in premenopausl patients with hormone-responsive breast cancer- Austrian Breast Cancer Study Group Trial 5. J Clin Oncol 2002 ; 20 : 4621-7.
26. Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, TU D, Paul N. A randomized trial comparing CEF to CMF in premenopausal women with node-positive breast cancer : update of NCIC CTG, MA.5. Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 17.
27. Citron M, Berry D, Cirrincione C, Carpenter J, Hudis C, Gradishar W, et al. Superiority of dose-dense over conventional scheduling and equivalence of sequential vs combination adjuvant chemotherapy for node-posirive breast cancer (CALGB 9741, INT C9741). Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 15.
28. Dieras V, Fumoleau P, Lotz JP, Ormetzguine Y, Sutherland W, Misset JL, the French Compassionate Use Program. Previous cumulative anthracycline dose is the main determinant of LVEF decrease in breast cancer patients treated with trastuzumab (Herceptin) : results of a French compassionate use program. Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 425
29. Gnant M, Hausmaninger H, Samonigg H, Mlieristch B, Taucher S, Luschin-Ebengreuth G, et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+ zoledronate) as adjuvant treatmenr for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter. Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 12
30. Massarweh S, Shou J, DiPietro M, Mohsin SK, Hilsenbeck SG, Wakeling AE, et al. Targeting the epidermal growth factdr receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. Breast Cancer Research and Treatment 2002; 76 (1), abstr 18
31. Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, et al. Predictive factors and response to letrozole vs tamoxifen. Breast Cancer Research and Treatment 2002 ; 76 (1), abstr 14
32. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1-1 and/or ErbB2-2-positive, estrogen receptor - positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001 ; 19: 3808-16.
33. Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002 ; 20: 1467-72.
34. Carlomagno C, Perrone F, Gallo C, et al. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996 ; 14: 2702-6
35. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997 ; 7 : 2518-25
36. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999 ; 79 : 1220-6
37. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000 ; 18 : 3471-9